Cart is empty From 2014 to 2021, uptake of disease-modifying treatments (DMTs) for sickle cell disease (SCD) remained low, according to a study published in the journal JAMA Network Open.
From 2014 to 2021, uptake of disease-modifying treatments (DMTs) for sickle cell disease (SCD) remained low, according to a study published in the journal JAMA Network Open.
Leave A Comment